Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enveric Biosciences filings document a biotechnology issuer focused on neuroplastogenic small-molecule drug candidates for psychiatric and neurological disorders. Its periodic and current reports address operating results, pipeline updates for EB-003 and related molecule series, intellectual-property matters, risk factors and the use of investor presentation materials in Regulation FD disclosures.
The company’s SEC record also covers capital-structure and governance matters, including registered direct and private placement financings, at-the-market offering registration, common stock, pre-funded warrants, Series G, H, I and J warrants, resale registration obligations, and Nasdaq-listed common stock. Proxy materials describe director elections, executive-compensation votes, auditor ratification, reverse stock split proposals and authorized-share proposals.
Enveric Biosciences, Inc. reported that Nasdaq has notified the company it is not meeting the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while Enveric’s Form 10-Q for the period ended June 30, 2025, reported stockholders’ equity of $2,184,769.
The company also does not meet Nasdaq’s alternative standards based on market value of listed securities or net income from continuing operations. Enveric has 45 calendar days, until October 10, 2025, to submit a plan to regain compliance, and Nasdaq may grant up to a 180-day extension if the plan is accepted. If the plan is not accepted, Enveric could appeal the determination to a Nasdaq Hearings Panel, and the company states that it intends to submit a compliance plan and monitor its stockholders’ equity.
Enveric Biosciences furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The filing also includes a machine-readable Interactive XBRL cover page (Exhibit 104). The Form states the press release and related information are furnished, not filed, and therefore are not subject to Section 18 liability or automatically incorporated by reference into future registration statements except by specific reference.
No numerical financial figures or earnings tables are included in the body of the Form 8-K itself; the substantive financial results are contained in the furnished press release. The filing is signed by Chief Executive Officer Joseph Tucker, Ph.D.